PeproTech Inc.
Originally published online as doi:10.1189/jlb.1107777 on April 2, 2008

Published online before print April 2, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1107777v1
84/4/994    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gasperini, P.
Right arrow Articles by Tosato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gasperini, P.
Right arrow Articles by Tosato, G.
(Journal of Leukocyte Biology. 2008;84:994-1000.)
© 2008 by Society for Leukocyte Biology

Contribution of viral and cellular cytokines to Kaposi’s sarcoma-associated herpesvirus pathogenesis

Paola Gasperini, Shuhei Sakakibara and Giovanna Tosato1

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA

1 Correspondence: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Building 37, Room 4124, Bethesda, MD 20892, USA. E-mail: tosatog{at}mail.nih.gov

ABSTRACT

Kaposi’s sarcoma (KS)-associated herpesvirus is associated with the proliferative/malignant disorders KS, primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD) in patients with AIDS. In spite of recent advances in the treatment of KS, PEL and MCD represent therapeutic challenges. Recent advances in dissecting the pathogenesis of these diseases have indicated that the viral cytokine IL-6 and the cellular cytokines/growth factors IL-10, IL-6, stromal cell-derived factor 1, and vascular endothelial growth factor are important contributors to the growth, survival, and spread of PEL and MCD and are therefore potential targets for drug development.

Key Words: primary effusion lymphoma • multicentric Castleman’s disease • angiogenesis • cell migration